Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of therapies for the treatment of various cardiometabolic disorders primarily abnormalities in blood lipids. The company offers Onemia, a medical food product for the dietary management of omega-3 phospholipids deficiency, and related abnormal lipid profiles and cardiometabolic disorders. It also develops CaPre, a prescription drug candidate for the prevention and treatment of cardiometabolic disorders, such as hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada.

Acasti Pharma Inc

Acasti Pharma, Inc. engages in the research, development, and commercialization of krill oil-based forms of omega-3 phospholipid therapies. It seeks to treat certain cardiometabolic disorders such as abnormalities in blood lipids, also known as dyslipidemia. It sproduct candidate, CaPre, is being developed to treat severe hypertriglyceridemia. The company was founded by Henri Harland on February 1, 2002 and is headquartered in Laval, Canada.

Should you buy, sell, or hold Acasti Pharma Inc (ACST) ?

Acasti Pharma Inc (ACST) : Buy or Sell